The GLP-1/GIP incretins are no different: from their discovery nearly 40 years ago, to their recent FDA approval(s) in obesity, we have walked through the story of how this class of medicines has emerged and developed over time
In turn, this can cause people to increase purging behaviors like using laxatives and vomiting, which can cause serious physical complications
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
GLP-1 drugs for type 2 diabetes and obesity have exploded in popularity for their ability to significantly cut peoples weight
Monitoring your glucose is vital for various reasons, even if you dont have diabetes